Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hybridization enhancement using microfluidic planetary centrifugal mixing.

Magdalena A Bynum1, Gary B Gordon

  • 1Agilent Laboratories, Agilent Technologies, 3500 Deer Creek Road, Palo Alto, California 94304, USA. maggie_bynum@agilent.com

Analytical Chemistry
|December 2, 2004
PubMed
Summary

This study introduces a novel microfluidics platform using planetary mixing for DNA microarrays. This method enhances sensitivity and sample conservation, improving gene signal detection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2017
Same author

Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.

The Lancet. Oncology·2017
Same author

Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management.

Anticancer research·2014
Same author

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Pharmacogenetics and genomics·2013
Same author

A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.

Chemotherapy·2012
Same author

A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2011

Area of Science:

  • Biotechnology
  • Microfluidics
  • Genomics

Background:

  • Achieving high sensitivity in DNA microarrays requires concentrated samples and effective mixing, which are difficult to combine.
  • Conventional methods for mixing concentrated samples in small chambers often result in imperfections and require extensive cleaning.
  • Diluting samples for better mixing in larger chambers compromises sensitivity.

Purpose of the Study:

  • To develop a microfluidics platform that effectively combines sample concentration and mixing for enhanced DNA microarray performance.
  • To overcome limitations of existing mixing techniques, such as sample loss and chamber scarring.
  • To improve sensitivity, dynamic range, and efficiency in microarray hybridizations.

Main Methods:

  • Introduction of a versatile two-axis centrifuge microfluidics platform.

Related Experiment Videos

  • Utilizing a planetary rotation of fluidic chambers within a radial gravitational field.
  • Employing thin chambers (50 micrometers) to overcome surface and viscous forces.

    • Main Results:

    • Achieved 10-fold increase in sensitivities and dynamic ranges by obviating sample dilution.
    • Detected 10,000 more usable signals compared to conventional mixing with the same amount of total RNA.
    • Demonstrated comparable results using one-tenth the starting sample volume with planetary mixing.

    Conclusions:

    • Planetary mixing in thin microfluidic chambers significantly enhances DNA microarray sensitivity and efficiency.
    • This technique conserves valuable samples, shortens hybridization times, and reduces the need for amplification.
    • Enables quantification of gene signals previously obscured by noise, advancing genomic analysis.